Literature DB >> 18275568

Varicella and the pregnant woman: prevention and management.

Andrew J Daley1, Susan Thorpe, Suzanne M Garland.   

Abstract

Infection with varicella zoster virus (VZV) is often considered a childhood 'right of passage'; however, primary infection occurring in women of child-bearing age can have significant adverse consequences both for the mother and for her fetus. During the first trimester, primary VZV infection may result in stillbirth or a baby born with the stigmata of the congenital varicella syndrome, while infection in the peripartum period can result in neonatal varicella, which carries a significant mortality rate despite appropriate antiviral therapy. Varicella in pregnant women can progress to pneumonitis and other severe sequelae that may also compromise the viability of the fetus. Exposure to VZV most commonly occurs in the community or from children in the household, but occasionally, exposure may occur in the hospital environment. Determining a woman's serostatus prior to pregnancy is advised, as effective vaccines are now available and should be administered to non-pregnant seronegative women of child-bearing age. Clinical practice guidelines for management of a pregnant woman exposed to VZV are presented.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18275568     DOI: 10.1111/j.1479-828X.2007.00797.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  13 in total

Review 1.  [Skin infections in pregnancy].

Authors:  R R Müllegger; M Glatz
Journal:  Hautarzt       Date:  2010-12       Impact factor: 0.751

2.  Comparison of DNA extraction methods from small samples of newborn screening cards suitable for retrospective perinatal viral research.

Authors:  Gai L McMichael; Amanda R Highet; Catherine S Gibson; Paul N Goldwater; Michael E O'Callaghan; Emily R Alvino; Alastair H MacLennan
Journal:  J Biomol Tech       Date:  2011-04

Review 3.  Varicella-zoster virus (chickenpox) infection in pregnancy.

Authors:  Ronald F Lamont; Jack D Sobel; D Carrington; Shali Mazaki-Tovi; Juan Pedro Kusanovic; Edi Vaisbuch; Roberto Romero
Journal:  BJOG       Date:  2011-05-18       Impact factor: 6.531

Review 4.  Viral pulmonary infection in pregnancy - Including COVID-19, SARS, influenza A, and varicella.

Authors:  Ashwini Maudhoo; Asma Khalil
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2022-07-09       Impact factor: 4.268

Review 5.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

6.  Follow-up of pregnant women exposed to chicken pox: an audit of relationship between level of antibody and development of chicken pox.

Authors:  E H Boxall; P A C Maple; P Rathod; E Smit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-01       Impact factor: 5.103

7.  Chicken pox in pregnancy : an obstetric concern.

Authors:  Viroj Wiwanitkit
Journal:  Indian J Dermatol       Date:  2010-10       Impact factor: 1.494

Review 8.  Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control Programs.

Authors:  Peter A C Maple
Journal:  Vaccines (Basel)       Date:  2015-12-09

9.  Seroprevalence of cytomegalovirus, Epstein Barr virus and varicella zoster virus among pregnant women in Bradford: a cohort study.

Authors:  Lucy Pembrey; Pauline Raynor; Paul Griffiths; Shelley Chaytor; John Wright; Andrew J Hall
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

10.  The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Haedicke; M Quinlivan; S P Steinberg; A A Gershon; K E Brown; J Breuer
Journal:  Epidemiol Infect       Date:  2016-03-28       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.